The induction of humoral and T cell immunity in this trial might relate to the underlying tumor histology, since RCC is known to be more immunogenic than other tumors [23,24] or could be due to the adjuvant effects of high-dose IL-2. Here, IL2 is linked to renal cell carcinoma.